Hidrocloruro De Efedrina Kabi (Ephedrine Hydrochloride)

Hidrocloruro De Efedrina Kabi is indicated for several conditions where stimulation of adrenergic receptors provides therapeutic benefit.

• Management of hypotension, especially acute episodes.
• Relief of bronchospasm in patients with bronchial asthma.
• Temporary reduction of nasal congestion associated with upper respiratory tract inflammation.
• Adjunctive treatment in certain cases of cardiac arrest to support blood pressure.
• Use as a bronchodilator in chronic obstructive pulmonary disease when other agents are insufficient.

• Ephedrine hydrochloride acts as a non‑selective adrenergic agonist. By stimulating both alpha‑ and beta‑adrenergic receptors, it induces vasoconstriction through α1 activation, increases heart rate and contractility via β1 stimulation, and relaxes bronchial smooth muscle through β2 activation. The combined central nervous system stimulation further enhances sympathetic outflow, contributing to its overall pressor and bronchodilatory effects and modestly elevates systemic vascular resistance.

Adverse reactions to ephedrine hydrochloride may vary in frequency, severity, and clinical presentation.

Common

• Palpitations or rapid heart rate (tachycardia) that may be transient.
• Mild to moderate rise in systolic and diastolic blood pressure, occasionally noticeable.
• Nervousness, restlessness, or fine hand tremor.
• Throbbing headache of varying intensity, often reported.
• Nausea, occasional vomiting, or abdominal discomfort.

Serious

• Cardiac arrhythmias such as ventricular tachycardia or atrial fibrillation.
• Severe hypertension that may progress to hypertensive emergency.
• Cerebral or myocardial ischemia presenting as chest pain or neurological signs.
• Pulmonary edema with shortness of breath and auscultatory crackles.
• Allergic reactions from rash and angioedema to anaphylactic shock, rarely fatal.

When prescribing ephedrine hydrochloride, clinicians should evaluate several safety considerations to minimize risk.

• Assess cardiovascular status, especially hypertension, arrhythmias, coronary artery disease, or recent myocardial infarction.
• Use caution in patients with hyperthyroidism, diabetes, glaucoma, or severe anxiety disorders.
• Avoid administration to individuals with known hypersensitivity to sympathomimetic amines or related compounds.
• Monitor fluid and electrolyte balance in patients at risk for dehydration or renal impairment.
• Limit use during pregnancy and lactation until a thorough risk–benefit assessment is completed.
• Adjust dose or discontinue therapy promptly if severe adverse reactions develop.

Ephedrine hydrochloride can interact with several medications, altering its efficacy or increasing the risk of adverse events.

Avoid

• Monoamine oxidase inhibitors (MAOIs) or recent MAOI therapy, due to risk of hypertensive crisis.
• β‑blockers, which may blunt bronchodilatory effects and precipitate severe hypertension.
• Tricyclic antidepressants, which can potentiate central nervous system stimulation.

Use with caution

• Diuretics, as they may enhance hypotensive or electrolyte disturbances.
• Antihypertensive agents, requiring close blood pressure monitoring.
• CNS stimulants such as caffeine or pseudoephedrine, which may increase sympathomimetic load.